Literature DB >> 10836525

Interleukin-6 serum concentration in ankylosing spondylitis: a reliable predictor of disease progression in the subsequent year?

A Falkenbach1, M Herold, R Wigand.   

Abstract

The aim of the present study was to evaluate whether in ankylosing spondylitis (AS), interleukin-6 (IL-6) is a reliable predictor of changes in mobility in the subsequent year. Of 261 AS patients who had been enrolled in a previous study, 128 returned for treatment at our health centre after 1 year (+/-3 months). The variables for mobility after 1 year (II) were compared with the findings of the previous year (I). Differences in parameters for mobility were related to the serum concentration of IL-6 in the previous year. Relation between serum concentration of IL-6 and difference (II-I) in occiput-to-wall distance (Spearman's rank correlation coefficient r(s), P value) was 0.02, 0.82; chin-chest distance -0.09, 0.31; cervical rotation -0.08, 0.39; chest expansion 0.05, 0.54; finger-floor distance -0.02, 0.84; Ott sign (flexibility of the thoracic spine) -0.11, 0.22; Schober sign 0.01, 0.94. After 1 year there was a significant improvement in cervical rotation in patients with low IL-6 serum concentration (lower quartile), but not in those with high levels of IL-6 (upper quartile). No further difference was seen between patients with high or low levels of IL-6. The present data suggest that the serum concentration of IL-6 does not allow a prediction of disease progression in the subsequent year.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10836525     DOI: 10.1007/s002960050119

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  2 in total

1.  Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity.

Authors:  Bingni Chen; Kunzhao Huang; Liang Ye; Yanqun Li; Jiawei Zhang; Jinshun Zhang; Xinmin Fan; Xiaokai Liu; Li Li; Jinxia Sun; Jing Du; Zhong Huang
Journal:  J Transl Med       Date:  2015-01-28       Impact factor: 5.531

2.  Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.

Authors:  S Visvanathan; C Wagner; J C Marini; D Baker; T Gathany; J Han; D van der Heijde; J Braun
Journal:  Ann Rheum Dis       Date:  2007-07-20       Impact factor: 19.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.